Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An astrocytic tumor occurring during adulthood. Representative examples include diffuse astrocytoma, anaplastic astrocytoma, and glioblastoma.
Biomarker and diagnostic research for adult astrocytic tumor has been reported in the published literature.
No approved treatments are currently available for adult astrocytic tumor. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for adult astrocytic tumor, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for adult astrocytic tumor. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
222 publications have been identified in PubMed for adult astrocytic tumor. Kisho has analyzed 88 by research type. Research spans Basic Science / Preclinical (24%), Review / Meta-Analysis (18%), and Clinical Trial Publication (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 21 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
Common questions about adult astrocytic tumor
Designated
Exclusivity End |
|---|
Designation Status |
|---|
ranagengliotucel-L | ranagengliotucel-L | NovaRx Corporation | 2009 | — | Designated |
Gene therapy approaches for adult astrocytic tumor have been reported in the published literature.
2 trials found
24%
Research summaries | 16 | 18% |
Clinical study results | 16 | 18% |
Disease patterns and progression | 15 | 17% |
Testing and diagnosis research | 10 | 11% |
Patient case studies | 6 | 7% |
New treatment approaches | 4 | 5% |
Mohile NA (2026). [PMID: 40300119](https://pubmed.ncbi.nlm.nih.gov/40300119/). *JCO Oncol Pract*. [Review / Meta-Analysis]
Piyadasa H (2026). [PMID: 41386224](https://pubmed.ncbi.nlm.nih.gov/41386224/). *Cancer Cell*. [Basic Science / Preclinical]
Campian JL (2026). [PMID: 41748622](https://pubmed.ncbi.nlm.nih.gov/41748622/). *Nat Commun*. [Clinical Trial Publication]
Seferbekova Z (2026). [PMID: 41783996](https://pubmed.ncbi.nlm.nih.gov/41783996/). *Neuro Oncol*. [Basic Science / Preclinical]
Colman H (2026). [PMID: 41325560](https://pubmed.ncbi.nlm.nih.gov/41325560/). *J Clin Oncol*. [Clinical Trial Publication]
Amezquita-Contreras C (2026). [PMID: 41926870](https://pubmed.ncbi.nlm.nih.gov/41926870/). *J Clin Neurosci*. [Epidemiology / Natural History]
Ghosh HS (2025). [PMID: 39584448](https://pubmed.ncbi.nlm.nih.gov/39584448/). *Neuro Oncol*. [Clinical Trial Publication]
Fawaz R (2025). [PMID: 40473546](https://pubmed.ncbi.nlm.nih.gov/40473546/). *Rev Neurol (Paris)*. [Epidemiology / Natural History]
Skredėnienė R (2025). [PMID: 40725030](https://pubmed.ncbi.nlm.nih.gov/40725030/). *Int J Mol Sci*. [Basic Science / Preclinical]
Aboubakr O (2025). [PMID: 39213667](https://pubmed.ncbi.nlm.nih.gov/39213667/). *J Neurosurg*. [Epidemiology / Natural History]